Company Description
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally.
The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis.
Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.
The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands.
In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss.
The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions.
Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
| Country | United States |
| Founded | 1923 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 10,000 |
| CEO | Kevin Ali |
Contact Details
Address: 30 Hudson Street, Floor 33 Jersey City, New Jersey 07302 United States | |
| Phone | 551 430 6900 |
| Website | organon.com |
Stock Details
| Ticker Symbol | OGN |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001821825 |
| CUSIP Number | 68622V106 |
| ISIN Number | US68622V1061 |
| Employer ID | 46-4838035 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kevin Ali | Chief Executive Officer and Director |
| Matthew M. Walsh C.F.A. | Executive Vice President and Chief Financial Officer |
| Joseph T. Morrissey Jr. | Executive Vice President and Head of Manufacturing and Supply |
| Dr. Juan Camilo Arjona Ferreira M.D. | Executive Vice President, Head of Research and Development and Chief Medical Officer |
| Kirke Weaver | Executive Vice President, General Counsel and Corporate Secretary |
| Rebecca Lowell Edwards | Chief Communications Officer |
| Daniel Karp | Head of Corporate Development |
| Aaron Falcione | Executive Vice President and Chief Human Resources Officer |
| Vittorio Nisita | Executive Vice President and Head of Enterprise Services and Solutions |
| Rachel A. Stahler | Chief Digital and Commercial Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 2, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 30, 2025 | SCHEDULE 13G/A | Filing |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 10-K | Annual Report |
| Feb 13, 2025 | 8-K | Current Report |
| Jan 21, 2025 | 8-K | Current Report |